|View printer-friendly version|
Array CEO Robert E. Conway to Speak at UBS Warburg Global Life Sciences Conference on Monday, October 8, 2001
BOULDER, Colo., Oct. 2 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Robert E. Conway, will speak at the UBS Warburg Global Life Sciences Conference on October 8 in New York City. The public is welcome to participate in the conference through the conference call facilities listed below.
UBS Warburg Global Life Sciences Conference
Robert E. Conway, Chief Executive Officer, Array BioPharma
Monday, October 8, 2001
Listen-only telephone conference lines:
The recorded line will be available for up to four weeks after the conference.
About Array BioPharma
Array BioPharma is a drug discovery company creating new drugs through the integration of chemistry, structural biology and chemoinformatics. Array collaborates with leading pharmaceutical and biotechnology companies to identify novel small molecule drugs and leverages its discovery platform to develop its own pipeline of proprietary drug candidates. The Array scientific team has a proven track record of success in identifying promising drug candidates.
Array BioPharma Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed below and described more fully in reports filed by Array with the Securities and Exchange Commission, including our final prospectus as filed on November 16, 2000. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with third parties on their drug discovery activities, the ability of our collaborators and of Array to meet drug discovery objectives tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of October 2, 2001. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
Array BioPharma's press releases are available at www.arraybiopharma.com.
SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, firstname.lastname@example.org/